The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Zhuravleva M.V.

I.M. Sechenov First Moscow State Medical University (Sechenov University);
Scientific Centre of Medical Application Expertise of the Ministry of the Healthcare of the Russian Federation

Kamchatnov P.R.

Pirogov Russian National Research Medical University

Vasyukova N.S.

Federal Scientific Center-all-Russian Research Skriabin and Kovalenko Institute of Experimental Veterinary Medicine the Russian Academy of Sciences

Arkhipov V.V.

Scientific Center for Examination of Medical Devices

Kuznetsova E.V.

Research Institute for Healthcare and Medical Management

Kameneva T.R.

Konchalovsky City Clinical Hospital

Serebrova S.Yu.

Scientific Center for Examination of Medical Devices;
Sechenov First Moscow State Medical University

Results of clinical studies of the efficacy and safety of the use of ethylmethylhydroxypyridine succinate in patients with chronic cerebral ischemia

Authors:

Zhuravleva M.V., Kamchatnov P.R., Vasyukova N.S., Arkhipov V.V., Kuznetsova E.V., Kameneva T.R., Serebrova S.Yu.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(11): 29‑39

DOI: 10.17116/jnevro202212211129

Views: 2651

Downloaded: 54

Download PDF (RU)
Contact the author
Table of contents

RESULTS OF CLINICAL STUDIES OF THE EFFICACY AND SAFETY OF THE USE OF ETHYLMETHYLHYDROXYPYRIDINE SUCCINATE IN PATIENTS WITH CHRONIC CEREBRAL ISCHEMIA
RESULTS OF CLINICAL STUDIES OF THE EFFICACY AND SAFETY OF THE USE OF ETHYLMETHYLHYDROXYPYRIDINE SUCCINATE IN PATIENTS WITH CHRONIC CEREBRAL ISCHEMIA

To cite this article:

Zhuravleva MV, Kamchatnov PR, Vasyukova NS, Arkhipov VV, Kuznetsova EV, Kameneva TR, Serebrova SYu. Results of clinical studies of the efficacy and safety of the use of ethylmethylhydroxypyridine succinate in patients with chronic cerebral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(11):29‑39. (In Russ.)
https://doi.org/10.17116/jnevro202212211129

Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Promising approaches to the pathogenetic therapy of amyotrophic late­ral scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):13-21
Long-term follow-up of adult patients with serial and status course of epileptic seizures. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):63-68
Resu­lts of a cohort single-center randomized study of the modu­lating effect of the drug Mexi­dol in the reha­bilitation of patients who suffered acute cere­bral insu­fficiency. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):108-117
Resu­lts of a pilot study of the stru­cture and evaluation of the therapy for chro­nic sleep diso­rders in como­rbid patients with chro­nic cere­bral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):118-126
Prevalence of cognitive impairment in older adults in the Russian Fede­ration. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):5-11
Comparative characteristics of neuropsychological and neurometabolic changes in patients with Alzheimer’s disease and vascular cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):17-24
Cognitive impairment in patients with arte­rial hype­rtension. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):41-48
Drug-induced cognitive impairment and deme­ntia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):77-85
Cognitive impairment in multiple system atro­phy — exclusion criteria or an inte­gral part of the clinical picture?. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):86-91
Effi­cacy and safety of choline alfo­scerate in the preventive therapy of deme­ntia in elde­rly patients with Mild Cognitive Impairment: a three-year prospective comparative study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):92-99

Chronic cerebral ischemia (CCI) is a common syndrome that, in the absence of adequate therapy, is characterized by a progressive course, an increase in cognitive, emotional, motor and other disorders, eventually leading to persistent disability of the patient. In the treatment of patients with CCI, the use of drugs with a multimodal neuroprotective effect is indicated. The results of the analysis of a series of clinical trials of the drugs Mexidol and Mexidol FORTE in patients with CCI are presented. The effects in relation to cognitive, emotional, asthenic, vegetative and other manifestations of CCI are considered. It is concluded that it is advisable to consistently use the drugs Mexidol and Mexidol FORTE in such patients.

Keywords:

chronic cerebral ischemia
cognitive impairment
Mexidol
emotional disorders
treatment

Authors:

Zhuravleva M.V.

I.M. Sechenov First Moscow State Medical University (Sechenov University);
Scientific Centre of Medical Application Expertise of the Ministry of the Healthcare of the Russian Federation

Kamchatnov P.R.

Pirogov Russian National Research Medical University

Vasyukova N.S.

Federal Scientific Center-all-Russian Research Skriabin and Kovalenko Institute of Experimental Veterinary Medicine the Russian Academy of Sciences

Arkhipov V.V.

Scientific Center for Examination of Medical Devices

Kuznetsova E.V.

Research Institute for Healthcare and Medical Management

Kameneva T.R.

Konchalovsky City Clinical Hospital

Serebrova S.Yu.

Scientific Center for Examination of Medical Devices;
Sechenov First Moscow State Medical University

Received:

26.09.2022

Accepted:

24.10.2022

List of references:

  1. Wardlaw JM, Smith EE, Biessels GJ, et al. STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822-838.  https://doi.org/10.1016/S1474-4422(13)70124-8
  2. Kulesh AA, Emelin AYu, Bogolepova AN, et al. Clinical manifestations and diagnostic issues of chronic cerebrovascular disease (chronic cerebral ischemia) at an early (pre-dement) stage. Nevrologiya, Nejropsihiatriya, Psihosomatika. 2021;13(1):4-12. (In Russ.). https://doi.org/10.14412/2074-2711-2021-1-4-12
  3. Haag MD, Hofman A, Koudstaal PJ, et al. Duration of antihypertensive drug use and risk of dementia: a prospective cohort study. Neurology. 2009;72(20):1727-1234. https://doi.org/10.1212/01.wnl.0000345062.86148.3f
  4. Diener HC, Sacco RL, Yusuf S, et al. Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) study group. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol. 2008;7(10):875-884.  https://doi.org/10.1016/S1474-4422(08)70198-4
  5. Reznik EV, Dzhioeva ON, Nikitin IG. Secondary prevention of stroke: the view of a therapist and cardiologist. Consilium Medicum. Neurology and Rheumatology. 2019;1:12-24. (In Russ.).
  6. Belova AN, Bogdanov EI, Voznyuk IA, et al. Therapy of moderate cognitive impairment in the early recovery period of ischemic stroke. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2021;121(5):1-7. (In Russ.). https://doi.org/10.17116/jnevro202112105133
  7. Pyshkina LI, Abieva AR, Yasamanova AN, et al. The Course of cerebrovascular pathology in patients with carotid artery stenosis. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2018;9(2):24-29. (In Russ.). https://doi.org/10.17116/jnevro20181180928
  8. Khripun AI, Salikov AV, Mironkov AB, et al. Results of endovascular treatment of acute tandem occlusion of the internal carotid and middle cerebral arteries. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2020;120(12-2):5-10. (In Russ.). https://doi.org/10.17116/jnevro20201201225
  9. Voronina TA. Antioxidants/antihypoxants: the missing puzzle piece in effective pathogenetic therapy for COVID-19. Infekc Bolezni. 2020;18(2):97-102. (In Russ.). https://doi.org/10.20953/1729-9225-2020-2-97-102
  10. Schulkin AV, Filimonova AA. Role of free radical oxidation, hypoxia and their correction in COVID-19 pathogenesis. Therapy. 2020;45(5):187-194. (In Russ.). https://doi.org/10.18565/therapy.2020.5.187-194
  11. Voronina TA. Mexidol: main neuropsychotropic effects and mechanisms of action. Farmateka. 2009;180(6):1-4. (In Russ.).
  12. Voronina TA. Pioner antioksidantnoy neyroprotektsii. 20 let v klinicheskoy praktike. Rossiyskiy Meditsinskiy Zhurnal. Nevrologiya. 2016;7:434-438. (In Russ.).
  13. Kraineva VA. The experimental study of peculiarities and mechanism of neuroprotective action of mexidol in hemorrhagic stroke. Bulletin of Experimental Biology and Medicine.2006;12(1):40-44. (In Russ.).
  14. Kirova YuI, Shakova FM, Germanova EL, et al. The effect of Mexidol on cerebral mitochondriogenesis at a young age and during aging. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2020;120(1):55-61. (In Russ.). https://doi.org/10.17116/jnevro202012001162
  15. Shalashova ML, Dudaeva NG, Golovacheva TV. The use of Mexidol in combination therapy with traditional antihypertensive agents in patients with arterial hypertension with signs of chronic cerebral vascular insufficiency. Bulletin of Experimental Biology and Medicine. 2006;1(7):152-155. (In Russ.).
  16. Semchenko LN, Drozdova TV, Zinovieva MN. The use of the drug Mexidol for the treatment of patients with chronic cerebrovascular insufficiency with vestibulocochlear manifestations. Bulletin of Experimental Biology and Medicine. 2006;1(5):75-79. (In Russ.).
  17. Shetekauri SA. Modern possibilities of antioxidant therapy and experience of Mexidol treatment in patients with chronic cerebrovascular insufficiency. Bulletin of Experimental Biology and Medicine. 2006;1(4):156-158. (In Russ.).
  18. Duma SN. Treatment of vertigo in elderly patients with chronic cerebrovascular pathology. Neurology, Neuropsychiatry, Psychosomatics. 2018;10(1):55-59. (In Russ.). https://doi.org/10.14412/2074-2711-2018-1-55-59
  19. Bolotova EV, Lushpai TYu, Kovrigina IV. Improving the effectiveness of treatment of hypertensive encephalopathy with mexidol. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2018;118(4):61-64. (In Russ.). https://doi.org/10.17116/jnevro20181184161-64
  20. Chukanova EI, Chukanova AS. Efficacy and safety of the drug mexidol FORTE 250 as part of sequential therapy in patients with chronic ischemia of the brain. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2019;119(9):39-45. (In Russ.). https://doi.org/10.17116/jnevro201911909139
  21. Antipenko EA, Deryugina AV, Gustov AV. Systemic stress-limiting effect of mexidol in chronic cerebral ischemia. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2016;116(4):28-31. (In Russ.). https://doi.org/10.17116/jnevro2016116412-6
  22. Tanashyan MM, Lagoda OV, Antonova KV. Chronic cerebrovascular diseases on the background of metabolic syndrome: new approaches to treatment. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2012;112(11):21-26. (In Russ.).
  23. Fedin AI, Zakharov VV, Tanashyan MM, et al. Results of an international multicenter, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2021;121(11):7-16. (In Russ.). https://doi.org/10.17116/jnevro20211211117
  24. Yanishevsky SN. Experience of using the drug Mexidol in the treatment of chronic cerebral circulatory insufficiency in patients with stenosing-occlusive lesions of the main brachycephalic vessels. Bulletin of Experimental Biology and Medicine. 2006;5(1):159-163. (In Russ.).
  25. Abramenko YuV. Evaluation of clinical efficacy, vasoactive and metabolic effects of exidol in elderly patients with dyscirculatory encephalopathy. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2011;111(11):35-41. (In Russ.).
  26. Chukanova EI, Chukanova AS, Mamaeva HI. Results of a study of the efficacy and safety of exidol in patients with chronic cerebral ischemia. Zhurnal Nevrologii I Psikhiatrii im. S.S. Korsakova. 2015;115(2):71-74. (In Russ.).
  27. Shchepankevich LA, Nikolaev YuA, Taneeva EV, et al. The efficacy and safety study of Mexidol and Mexidol FORTE 250 in patients with chronic cerebral ischemia. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2021;121(10):32-37. (In Russ.). https://doi.org/10.17116/jnevro202112110132
  28. Karpikova NI, Peteryukhina AA. The use of the drug Mexidol for the treatment of patients with diseases of the cerebral vessels. Bulletin of Experimental Biology and Medicine. 2006;6(1):32-33. (In Russ.).
  29. Smirnova IN, Fedorova TN, Tanashyan MM, Suslina ZA. Clinical efficacy and antioxidant activity of Mexidol in chronic cerebrovascular diseases. Nervous Diseases. 2006;12(1):33-36. (In Russ.).

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.